Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $10.4500 (-0.38%) ($10.2500 - $10.6500) on Tue. Feb. 26, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.62% (three month average) | RSI | 68 | Latest Price | $10.4500(-0.38%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 0.4% a day on average for past five trading days. | Weekly Trend | IOVA advances 2.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(48%) ARKG(47%) IWO(43%) ARKK(41%) | Factors Impacting IOVA price | IOVA will decline at least -2.31% in a week (0% probabilities). VXX(-13%) VIXM(-8%) UUP(-7%) IFRA(-4%) TLT(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.31% (StdDev 4.62%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $10.1(3.47%) | 10 Day Moving Average | $10.05(3.98%) | 20 Day Moving Average | $9.74(7.29%) | To recent high | -0.4% | To recent low | 39.1% | Market Cap | $1.53b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |